Lundbeck has named former Bayer director Barbara Jaszewski as its new VP, global pricing and market access.
Jaszewski has great experience in this type of role, serving most recently as director of global market access of Bayer Healthcare for the EMEA region and Canada.
This was her most senior role in a ten year career at Bayer that included several years in Canada as director of reimbursement.
Jaszewski has also spent time at GSK, where she was reimbursement strategist.
Lundbeck’s senior VP, global product strategy and portfolio development Andrea Eggert commented on the appointment.
He said: “Barbara Jaszewski will play an important role in leading our efforts to further strengthen Lundbeck’s commercial business processes, and will help our organisation support future product launches in the best way possible.”
Jaszewski’s most pressing task will be to lead the launch of Selincro (nalmefene), which was recently recommended by the European Medicines Agency (EMA) to treat alcohol dependence.
In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.